| Name | Title | Contact Details |
|---|
At Akorn, we develop, manufacture and market specialty pharmaceuticals, including prescription, consumer health and animal health products. As an industry leader in branded and generic products in alternate dosage forms such as ophthalmics, injectables, oral liquids, otics, topicals, inhalants and nasal sprays, we focus each day on our mission to improve lives, through the quality, availability and affordability of our products. Akorn has Research and Development facilities in Vernon Hills, IL and Cranbury, NJ that provide a robust and continuous pipeline of new products. Akorn`s manufacturing facilities are located in Decatur, IL; Somerset, NJ; Amityville, NY and Hettlingen, Switzerland. In anticipation of long-term, substantial growth, we offer challenging, attractive career opportunities along with competitive salaries and comprehensive benefits. Akorn is an Equal Opportunity Employer. M/F/V/D.
Apicore, LLC is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
GTC Biotherapeutics, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to transform the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which is being evaluated in two pivotal Phase 3 studies and has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule (ORMD-0901).
Virtus Pharmaceuticals’ mission is to be the leading specialty niche pharmaceutical company providing the highest quality products through experienced leadership, innovative approaches and outstanding customer service.